Skip to content

The use of stem cells for the treatment of the cartilage lesions

Comparison of Transplantation of Mesenchymal Stem Cells and Autologous Chondrogenic Pre-Differentiated Mesenchymal Stem Cells for the Treatment of Cartilage Lesions of knee joint

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017052634053N2
Enrollment
16
Registered
2017-07-13
Start date
2017-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Destructive lesions of the knee joint cartilage. Disorder of cartilage, unspecified

Interventions

Intervention 1: Control group: This group will receive only autologous mesenchymal stem cells. One to two million cells are spilled in the alginate bed and the medium is changed every three days until
Treatment - Other
Control group: This group will receive only autologous mesenchymal stem cells. One to two million cells are spilled in the alginate bed and the medium is changed every three days until the alginate is
Intervention group: This group receives autologous chondrogenic pre-differentiated mesenchymal stem cells (MSCs). One to two million cells are spilled in the alginate bed and the medium is changed eve

Sponsors

Hamadan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: aged between 15 years to 40 years; the lesion between 2.5 and 6 square centimeters; the lesions of trauma sports and non-sports injury; femoral condyle internal or external lesions Exclusion criteria: Obesity; corticosteroid injection less than 3 months ago; hyaluronic acid injection less than 6 months ago; varus and valgus more than 5 degree; diabetes type one and two; autoimmune disease; malnutrition; certain neurological diseases; history of allergy; infectious diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Articular cartilage lesions of the knee. Timepoint: 3.6.12,18 weeks. Method of measurement: MRI and diagnostic arthroscopy.

Secondary

MeasureTime frame
Glycosaminoglycans, collagen, gene and protein expression of, agercan, collagen type II and sox9. Timepoint: Eighteenth week. Method of measurement: biochemical, molecular and immunocytochemistry analysis.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarjam Goudarzi

Hamadan university of medical sciences

farjam.goudarzi@gmail.com+98 81 3821 4454

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026